Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | GRIK1 | P39086 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309322 | 0.99 | HSD17B10 (0.66) | HSD17B10TSHRGRIK1KMT2AKDM4E | |
| SCHEMBL29964652 | 0.93 | TSHR (0.65) | HSD17B10TSHRGRIK1KMT2AKDM4E | |
| SCHEMBL29964657 | 0.93 | TSHR (0.65) | HSD17B10TSHRGRIK1KMT2AKDM4E | |
| SCHEMBL28734364 | 0.82 | KMT2A (0.58) | KMT2AKDM4EMEN1ALDH1A1CYP2C19 | |
| SCHEMBL29721812 | 0.82 | KMT2A (0.58) | KMT2AKDM4EMEN1ALDH1A1CYP2C19 | |
| SCHEMBL2270149 | 0.82 | ACLY (0.57) | HSD17B10KDM4EALDH1A1 | |
| SCHEMBL4602392 | 0.81 | HDAC1 (0.56) | HSD17B10KDM4EALDH1A1GRM5 | |
| SCHEMBL1463554 | 0.81 | RAB9A (0.67) | HSD17B10TSHRGRIK1KMT2AMEN1 | |
| SCHEMBL14544782 | 0.80 | KMT2A (0.47) | HSD17B10TSHRKMT2AKDM4EMEN1 | |
| SCHEMBL7814976 | 0.79 | ALDH1A1 (0.68) | HSD17B10TSHRKDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | PIM1, PIM3, PIM2 | HSD17B10 4168/4885TSHR 1916/4885GRIK1 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.